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Abstract
Background: Increased numbers of tumour-associated macrophages correlate with shortened survival in some
cancers. The molecular bases of this correlation are not thoroughly understood. Events triggered by CXCL12 may
play a part, as CXCL12 drives the migration of both CXCR4-positive cancer cells and macrophages and may
promote a molecular crosstalk between them.
Results: Samples of HER1-positive colon cancer metastases in liver, a tissue with high expression of CXCL12, were
analysed by immunohistochemistry. In all of the patient biopsies, CD68-positive tumour-associated macrophages
presented a mixed CXCL10 (M1)/CD163 (M2) pattern, expressed CXCR4, GM-CSF and HB-EGF, and some stained
positive for CXCL12. Cancer cells stained positive for CXCR4, CXCL12, HER1, HER4 and GM-CSF. Regulatory
interactions among these proteins were validated via experiments in vitro involving crosstalk between human
mononuclear phagocytes and the cell lines DLD-1 (human colon adenocarcinoma) and HeLa (human cervical
carcinoma), which express the above-mentioned ligand/receptor repertoire. CXCL12 induced mononuclear
phagocytes to release HB-EGF, which activated HER1 and triggered anti-apoptotic and proliferative signals in
cancer cells. The cancer cells then proliferated and released GM-CSF, which in turn activated mononuclear
phagocytes and induced them to release more HB-EGF. Blockade of GM-CSF with neutralising antibodies or siRNA
suppressed this loop.
Conclusions: CXCL12-driven stimulation of cancer cells and macrophages may elicit and reinforce a GM-CSF/HB-
EGF paracrine loop, whereby macrophages contribute to cancer survival and expansion. The involvement of mixed
M1/M2 GM-CSF-stimulated macrophages in a tumour-promoting loop may challenge the paradigm of tumour-
favouring macrophages as polarized M2 mononuclear phagocytes.
Background
Over the last few years, a great deal of attention has
been paid to the clinical significance of macrophages
that infiltrate cancer. A number of studies provide evi-
dence that tumour-associated macrophages are a nega-
tive prognostic factor of survival [1,2]. A recent gene-
profiling study demonstrates that the overexpression of
a macrophage signature and an increased number of
tumour-infiltrating macrophages in diagnostic lymph-
nodes are associated with poor outcome in classic
Hodgkin’s lymphoma patients [3]. Other studies under-
line pathways leading to M2 macrophage responses that
foster tumour growth [4-7]. In the end, all these studies
deal with the crosstalk between tumour cells and macro-
phages. For instance, a regulatory loop between breast
cancer cells and macrophages has been described [8],
and the cellular expression of matrix metallopeptidase
11 seems to be relevant to disease outcome at least in
classic Hodgkin’s lymphoma [3]. However, the grounds
on which the above-mentioned prognostic significance
rests are not so thoroughly appreciated, especially in
terms of cell-to-cell molecular mechanisms.
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and cancer cells, we tried to tease out the role that
CXCL12 plays in both cancer cells and macrophages at
the boundaries between cancer and inflammation. A
tissue with high expression of CXCL12 (for example,
liver or bone marrow) may represent a site that prefer-
entially attracts both macrophages [9] and cancer cells
[10,11], which co-migrate depending on their expres-
sion of the CXCL12 receptors CXCR4 and/or CXCR7
[12]. Ligand binding to these receptors, which are
heterotrimeric guanine nucleotide-binding protein-
coupled receptors (GPCR), activates matrix metallo-
peptidases that cleave EGF-family ligands, such as EGF
or HB-EGF, from the cell membrane [13], leading to
transactivation of HER1 on neighbouring cells [14].
This transactivation mechanism is a general function
of GPCR signalling [15]. HER1 expressed by epithelial
cancers plays a pivotal role by transducing signals that
favour tumour progression [16,17]. The macrophage-
regulator GM-CSF, which is produced by some types
of cancer cells [18,19], specifically induces HB-EGF in
macrophages and neutrophils [20].
Because mononuclear phagocytes express both
CXCL12 GPCRs and HB-EGF, we argued that the
recruitment of mononuclear phagocytes to a site of
metastasis such as liver through CXCL12 should induce
a release of HB-EGF, which is expected to activate
HER1 and favour tumour progression. We found that
tumour-associated macrophages and metastatic HER1-
positive colon cancer in liver biopsies expressed a
ligand/receptor repertoire that was consistent with our
hypothesis and that in vitro CXCL12 could trigger a
GM-CSF/HB-EGF paracrine loop whereby mononuclear
phagocytes support cancer survival.
Methods
Ethical requirements
The blood and histological samples used in our study
were in compliance with Institutional Review Board
regulations.
Cells and reagents
Highly purified human mononuclear phagocytes and
neutrophils were isolated from the buffy coats [21] of
blood samples from healthy volunteers. HeLa (human
cervical carcinoma), DLD-1 (human colon adenocarci-
noma) and Balb/c 3T3 (Swiss mouse embryo) cell lines
(purchased from ATCC, Manassas, VA) and HUVEC
(human umbilical vein endothelial cells, purchased from
Cambrex, Walkersville, VA) were also used. Non-adher-
ent and adherent cells were grown in RPMI-1640 med-
ium and DMEM or TC199 + 10% FCS (complete
medium; Invitrogen, Carlsbad, CA), respectively. Cells
were treated with 200 ng/mL CXCL12 (Peprotech,
London, UK) or 25 ng/mL GM-CSF (Genetics Institute,
Boston, MA) or 25 ng/mL HB-EGF or 100 μg/mL anti-
HB-EGF or 100 μg/mL anti-GM-CSF neutralising
monoclonal antibody (mAb) (R&D Systems, Minneapo-
lis, MN) or isotypic control immunoglobulins. After
growing in cultures for the appropriate times in differ-
ent conditions, the cells were either lysed for total RNA
extraction or used for functional assays. In some experi-
ments, the conditioned medium was replaced with fresh
medium after 24 hours of stimulation and the cells were
then maintained in culture for up to 48 hours. Cell-free
supernatants (SN) were stored at -80°C.
Immunochemistry on tissues and cells
Histological samples were obtained by hepatic lobect-
omy to excise metastatic nodules derived from colon
cancer. After surgical excision, samples were put in buf-
fered formalin, treated in an automated processor and
embedded in paraffin. Four micrometre-thick slices were
cut from paraffin blocks onto adhesive-coated slides.
Cytological samples were obtained by allowing cells to
grow on the slides. Antibodies (Ab) used included the
following: CD163 (clone 10D6, 1/200; Novocastra, New-
castle-upon-Tyne, UK), CXCL10 and CXCR4 (both rab-
bit polyclonal, 1/500 and 1/100, respectively; Abcam,
Cambridge, UK), CXCL12 (clone 7918, 1/100), GM-CSF
(clone 3209, 1/100), HER1 (1/100), HER4 (1/100), and
HB-EGF (clone 125923, 1/200) (all purchased from
R&D Systems). Antigen retrieval was performed for all
antibodies in a hot bath for 30 minutes at pH 6 (except
for GM-CSF retrieval, which was performed at pH 8).
F o rG M - C S Fa n dH B - E G Fn oH 2O2 blocking was per-
formed. As controls, sequential sections or cytological
slides were incubated with the Ab diluent and indiffer-
ent isotypic Ab. All procedures were performed on an
automated stainer (Bond, Vision Biosystems, Melbourne,
AU) using a polymer detection system (NovoLink,
Novocastra).
Flow cytometry
Following stimulation for 20 minutes or 24 hours with
CXCL12, 1 × 10
6 cells were incubated with a goat anti-
human HB-EGF IgG polyclonal Ab (Oncogene, San
Diego, CA) or an IgG control Ab. After washing, 5 μLo f
phycoerythrin-conjugated swine anti-goat IgG (Caltag
Laboratories, Burlingame, CA) was added. The cells were
then analysed on a FACSCalibur (Becton-Dickinson,
Mountain View, CA) using the FlowJo 8.8.2 program
(Tree Star, Ashland, OR).
HER1 transactivation assay
Cellular release of HB-EGF was evaluated by measuring
its effect on HER1 phosphorylation at tyrosine 1068
(Y1068) using HeLa and DLD-1 as target cells.
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6effector cells (mononuclear pha-
gocytes and neutrophils) were seeded in the upper
chamber of a 0.4 μm transwell co-culture system
(Costar, Cambridge, MA) and were stimulated with
CXCL12 for 20 minutes. In a separate experiment,
3×1 0
6 mononuclear phagocytes and neutrophils were
cultured in the presence or absence of CXCL12 for 24
hours and their conditioned medium was added to the
target cells for 20 minutes. HeLa cells were also stimu-
lated for 20 minutes with recombinant human HB-EGF.
Subconfluent HeLa cells that had been starved for 24
hours were incubated in the presence or absence of the
anti-HB-EGF neutralisingA b( R & DS y s t e m s ) .T a r g e t
cells were harvested for protein extraction.
Protein extraction
Cell pellets were lysed for 30 minutes in 1 mL ice-cold
cell extraction buffer (Biosource, Camarillo, CA), which
was supplemented with a protease inhibitor cocktail
(Sigma, St. Louis, MO) and 1 mM PMSF (Sigma). After
centrifugation at 13,000 rpm for 10 minutes at 4°C, ali-
quots of the SN were stored at -80°C.
Mass spectrometry
Approximately 1 × 10
7 HeLa cells, which were either
untreated or treated with HB-EGF for 20 minutes, were
harvested for HER1 immunoprecipitation, reduction,
alkylation and tryptic digestion. Ten microliters of the
peptide mixture was analysed by means of an LCMS/
MS system [22]. The data handling for the identification
of phosphorylated residues was performed according to
Guo et al. [23]. HB-EGF-induced HER1 phosphorylation
was evaluated at Y992, Y1045, Y1068, Y1086, S1142,
Y1148, Y1173, and expressed as phosphorylation ratio
(phosphorylation after stimulus/basal phosphorylation).
ELISA
1. HER1 pY1068 and ERK1/2 pTpY185/187.T o t a lH E R 1
versus HER1 pY1068 and total ERK1/2 versus ERK1/2
pTpY-185/187 were measured in cell protein extracts
using a commercially available ELISA (Biosource). The
results were calculated as the ratio of phosphorylated
molecules to total molecules and expressed as the per-
centage of phosphorylation. 2. HB-EGF and GM-CSF.
The cell-free culture SN was assayed for soluble HB-EGF
protein using a specific ELISA developed in our labora-
tory [20] and for GM-CSF using a commercial ELISA
(R&D Systems). Only SN previously purified from HB-
EGF or GM-CSF by specific crosslinking (Invitrogen)
were subsequently used as agonistic SN to induce HB-
EGF or GM-CSF, respectively, in cell stimulation experi-
ments followed by ELISA tests. 3. Apoptosis. 72-hour
internucleosomal DNA fragmentation as an index of
apoptosis was evaluated using a cell death detection
ELISA (Roche Diagnostics, Mannheim, DE) and
expressed as the mean ± SD of triplicate determinations
of the enrichment factor (absorbance of unstimulated
cells/absorbance of stimulated cells).
Northern blotting
Total RNA was extracted from the indicated cells.
Northern blot analysis (with 10 μg RNA/lane) was per-
formed as described [19]. Filters were hybridised with
32P-labelled cDNA probes complementary to the HB-
EGF RNA sequence, which were generated in our
laboratory or with a
32P-labelled plasmid containing a
cDNA probe that detected the b-actin RNA sequence.
RT-PCR
Total cellular RNA was purified by the QIAamp RNA
Blood mini kit (Qiagen, Hilden, DE) + DNase digestion
(Qiagen). Templates were generated from 2 μgo fR N A
with the Superscript III First-Strand Synthesis System
kit (Invitrogen). cDNA for GM-CSF was amplified using
the following primers (Invitrogen): 5’-CTCA-
GAAATGTTTGACCTCCAG-3’ (sense) and 5’-TGA-
CAAGCAGAAAGTCCTTCAG-3’ (antisense) for a 221
bp amplicon. The GAPDH internal control primers
(SuperArray Bioscience, Frederick, MD) were used to
co-amplify a specific fragment that was 436 bp long.
After 30 cycles at 95°C for 15”, 55°C for 30” and 72°C
for 30” in a Veriti thermal cycler (Applied Biosystems,
Foster City, CA) using the AmpliTaq Gold PCR master
mix (Applied Biosystems), the reactions were analysed
by agarose gel electrophoresis and recorded using a Ver-
saDoc imaging system (Bio-Rad, Hercules, CA).
Cell proliferation and apoptosis
Hela, DLD-1, HUVEC and Balb/c 3T3 cells were seeded
in 96-well plates in completem e d i u ma n da l l o w e dt o
adhere for 24 hours. They were then incubated in the
absence or presence of the anti-HB-EGF neutralizing Ab
(R&D Systems) and were stimulated with 25 ng/mL HB-
EGF. In selected experiments, HeLa and DLD-1 were
deprived of serum and cultured in the absence or pre-
sence of HB-EGF. Cell proliferation was measured by
MTT incorporation [19] at 24, 48 and 72 hours and
expressed as the proliferation index. Apoptosis was mea-
surerd as the internucleosomal DNA fragmentation
enrichment factor at 72 hours (see ELISA).
siRNA knockdown
To silence the expression of GM-CSF, HeLa and DLD-1
cells were seeded on glass slides (10
5 cells/mL), stimu-
lated with 200 ng/mL CXCL12 and/or 25 ng/mL
HB-EGF or SN from GM-CSF-stimulated mononuclear
phagocytes and transfected 48 hours using HiPerFect
Transfection Reagent and siRNA (2 nM and 5 nM
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Stars negative control siRNA - Alexa Fluor 488; Qiagen).
Transfection efficiency (> 95%) was determined by flow
cytometry on trypsinized cells. Effective silencing of
GM-CSF was determined by testing the induction and
release of 1. GM-CSF in cancer cells (using immunohis-
tochemistry and ELISA, after a 24-hour stimulation with
HB-EGF or mononuclear phagocytes conditioned med-
ium) and 2. HB-EGF in mononuclear phagocytes (using
flow cytometry and ELISA, after a 24-hour stimulation
with silenced cancer cell SN).
Statistics
Student’s t-test, Mann-Whitney U test and Kruskall-
Wallis ANOVA by ranks were used. Differences were
considered significant for p values < 0.05.
Results
Macrophages infiltrate colon cancer metastases in liver
We analysed the histological pattern of surgical samples
from 15 patients aged 60 to 79 who underwent hepatic
lobectomy in order to excise metastatic colon cancer
nodules. In Figure 1, we show the representative histol-
ogy from a 76-year-old patient who had such a proce-
dure. Serial preparations of a subglissonian metastatic
nodule were stained by immunohistochemistry for
CD68, CXCL10, CD163, CXCR4, CXCL12, GM-CSF,
HER1, HER4 and HB-EGF. Macrophages, which were
found to infiltrate the metastatic region often creating a
bridge between perivascular zones and metastases, were
intensely positive for CD68, CXCR4, GM-CSF and HB-
EGF; some were CXCL12-positive. Of interest, macro-
phages stained positive for both CXCL10 (M1-marker)
and CD163 (M2-marker). Though we could not perform
a double staining, the distribution of the expression of
CXCL10 and CD163 suggests a cellular co-expression
rather than distinct populations of cells. In any case, the
macrophages were not definitely polarized towards a
typical M2 pattern but instead showed a mixed M1/M2
pattern. The cancer cells were positive for CXCR4,
CXCL12, HER1, HER4 (a chemotactic receptor that
responds to HB-EGF), and GM-CSF. The cellular distri-
bution of ligands and receptors suggested specific inter-
plays that were tested in the following experiments
performed on the HeLa and DLD-1 cancer cell lines,
which express the same pattern of molecules, and on
human mononuclear phagocytes ex vivo.
CXCL12 induces HB-EGF synthesis and release in
mononuclear phagocytes
Under basal conditions, mononuclear phagocytes
express HB-EGF (Figure 2A, B). When we stimulated
mononuclear phagocytes with 200 ng/mL CXCL12, the
membrane density of HB-EGF was initially reduced (at
20 minutes), but was increased after 24 hours
(Figure 2A). After a 2-hour stimulation, constitutive
HB-EGF mRNA transcripts were up-regulated in mono-
nuclear phagocytes (Figure 2B), and this effect increased
up to 24 hours (data not shown). This induction of HB-
EGF was cell type specific. For instance, we show in Fig-
ure 2B that neutrophils did not express HB-EGF tran-
scripts either basally or after CXCL12 stimulation. A 1-
hour stimulation of mononuclear phagocytes with
CXCL12 determined an increase in the HB-EGF con-
centration in the culture supernatants (Figure 2C).
Thus, CXCL12-dependent signals induce mononuclear
phagocytes to release HB-EGF from the cell membrane,
increase the amounts of HB-EGF transcripts at 2 hours,
and upregulate HB-EGF synthesis, leading to an increase
in membrane-bound HB-EGF at 24 hours.
HB-EGF-dependent HER1 phosphorylation
To test if the stimulation of mononuclear phagocytes
with CXCL12 could induce HER1 transactivation in
bystander cells via HB-EGF shedding, we performed
transwell co-cultures, in which we analysed HER1 phos-
phorylation at tyrosine 1068. Tyrosine 1068, a major site
of autophosphorylation that is associated with the acti-
vation of Ras, MEK and ERK1/2 [24] was chosen after
performing mass spectrometry analysis of ligand-
dependent HER1 phosphorylation in HeLa cells. Mass
spectrometry confirmed that 25 ng/mL HB-EGF induced
a phosphorylation pattern different from that induced by
other HER1 ligands [23,24] and that Y1068 phosphory-
lation was induced by HB-EGF in either HeLa or DLD-1
cells (Figure 3A). Moreover, HB-EGF-dependent phos-
phorylation was coupled to phosphorylation of ERK1/2
a tt h r e o n i n e1 8 5a n dt y r o s i n e1 8 7( F i g u r e3 B ) ,a s
expected [24].
CXCL12-driven release of HB-EGF from mononuclear
phagocytes transactivates HER1 and supports
proliferative, anti-apoptotic and angiogenic effects in
bystander cells
To determine if CXCL12 induces the transactivation of
HER1, we performed the transwell experiments depicted
in Figure 4. Mononuclear phagocytes (and neutrophils
as negative control) in the upper chamber were stimu-
lated with 200 ng/mL CXCL12 and HER1-positive
HeLa, DLD-1, Balb/c 3T3 cells and HUVEC were used
in the lower chamber as target cells. After 20 minutes,
the cells were analysed to assess HER1 phosphorylation
at tyrosine 1068. Figure 4A depicts several negative con-
trols. The direct stimulation of HeLa, DLD-1, Balb/c
3T3 cells and HUVEC with CXCL12 did not induce
HER1 phosphorylation. Unstimulated mononuclear pha-
gocytes did not induce HER1 phosphorylation in the
target cells. Neutrophils, which do not express HB-EGF
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Page 4 of 13Figure 1 Ligand/receptor repertoire in metastatic colon cancer and infiltrating macrophages. Serial preparations of a surgically removed
hepatic, subglissonian colon cancer nodule (★) were stained with Abs against the specified molecules. Infiltrating CD68-positive macrophages
(☆), which bridge perivascular zones to gland-like structures built up by metastatic colon cancer cells, stained positive for CXCL10 (a M1-marker)
and CD163 (a M2-marker) indicating a mixed M1/M2 environment. They preferentially stained positive for CXCR4, GM-CSF, HB-EGF and CXCL12.
Cancer cells were positive for HER1, HER4, CXCR4 and CXCL12, and to a lesser extent, GM-CSF. The role of these molecules in the crosstalk
between tumour-associated macrophages and cancer cells was evaluated in the following experiments. Boxes delineate regions shown below at
higher magnification (400×). H/E: a haematoxylin/eosin staining of the metastatic nodule (★) showing its hepatic topography among
macrophages (☆) at low magnification (40×). A representative case out of 15 is shown.
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Page 5 of 13[20], were treated with CXCL12 and this treatment did
not lead to phosphorylation of HER1 at tyrosine 1068 in
the target cells. In contrast, as depicted in Figure 4B,
treatment of mononuclear phagocytes with CXCL12 led
to the strong phosphorylation of Y1068 in all of the tar-
get cells. Pre-treatment with 100 μg/mL of neutralising
anti-HB-EGF, but not its corresponding controls, inhib-
ited the transactivation of HER1. Finally, supernatants
from CXCL12-stimulated neutrophils, which did not
produce HB-EGF, were not effective (SN1, Figure 5A, B,
C). Mononuclear phagocytes-derived supernatants (SN2,
Figure 5A) contained factors that led to HER1 phos-
phorylation in, and proliferation of, HeLa and DLD-1
cells (Figure 5B, C) as well as HUVEC and Balb/c 3T3
Figure 2 CXCL12 modifies HB-EGF expression in mononuclear
phagocytes. Human mononuclear phagocytes (Mø) were cultured
alone or in the presence of 200 ng/mL CXCL12. Cells were collected
after 20 minutes, 2 hours and 24 hours; cell-free supernatants were
collected after 24 hours and the levels of soluble HB-EGF protein
were measured using a specific ELISA. (A) Flow cytometric analysis
showing that CXCL12-stimulated Mø released HB-EGF (after 20
minutes) and up-regulated its expression (after 24 hours). (B)
Northern blot analysis on Mø and neutrophils (PMN, used as
negative control) collected after 2 hours of stimulation with CXCL12.
Only Mø produced detectable levels of HB-EGF mRNA in basal
conditions, and HB-EGF transcripts were up-regulated upon
stimulation. After 24 hours, the mRNA up-regulation persisted (data
not shown). (C) CXCL12 treatment induced Mø to release HB-EGF
into the culture medium (p < 0.05). Representative pictures or the
means ± SD out of 10 experiments are shown.
Figure 3 HB-EGF-induced HER1 phosphorylation.( A )H E R 1
autophosphorylation pattern derived from mass spectrometry
analysis of trypsin-digested peptides from HeLa cells stimulated with
25 ng/mL HB-EGF for 20 minutes. Seven phosphorylation sites are
represented as phosphorylation ratio (phosphorylation after
stimulus/basal phosphorylation). (B) HeLa and DLD-1 cells were
stimulated with 25 ng/mL HB-EGF for 20 minutes. Phosphorylation
of HER1 and ERK1/2 was measured by ELISA and is expressed as
phosphorylated molecules/total molecules and represented as per
cent ratio. The means ± SD of 10 experiments are depicted.
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Page 6 of 13cell proliferation (SN2, Figure 6A). Blockade of HB-EGF
with the neutralising Ab abolished the phosphorylation
and the proliferation of the cells (Figures 4B; 5B, C; 6A).
However, this effect did not occur when using indiffer-
ent isotypic immunoglobulins. Thus, CXCL12 induced
the release of functional HB-EGF from mononuclear
phagocytes, transactivation of HER1 and proliferation of
cancer cells (HeLa and DLD-1), fibroblasts (Balb/c 3T3
cells) and endothelial cells (HUVEC). This occurred
both in transwell co-cultures and after adding condi-
tioned medium (from cultures of mononuclear phago-
cytes stimulated with CXCL12) to the target cells.
Figure 4 CXCL12-dependent transactivation of HER1 in
transwell experiments. Human mononuclear phagocytes (Mø) and
neutrophils (PMN, used as negative control) were stimulated with
200 ng/mL CXCL12 in the upper chamber of a transwell containing
HeLa, DLD-1, Balb/c 3T3 or HUVEC target cells in the lower
chamber. HeLa, DLD-1, Balb/c 3T3 and HUVEC were collected after
20 minutes of stimulation, and HER1 phosphorylation at Y1068 was
measured by an ELISA using specific anti-tyrosine mAbs, expressed
as phosphorylated molecules/total molecules and represented as a
per cent ratio. (A) Negative controls: CXCL12 alone, stimulated PMN
or unstimulated Mø were ineffectual. (B) Effect of Mø stimulation:
CXCL12 led to HER1 transactivation in either HeLa, DLD-1, Balb/c
3T3 or HUVEC (p < 0.05). Pre-treatment with 100 μg/mL anti-HB-EGF
neutralising Ab abolished Y1068 phosphorylation in the target cells
(p < 0.05). The isotypic control of neutralising anti-HB-EGF mAb was
not effective. The colour pattern of the bars refers to each type of
target cell. The means ± SD of 10 experiments are depicted.
Figure 5 Proliferation induced by supernatants from CXCL12-
stimulated mononuclear phagocytes. (A) Human mononuclear
phagocytes (Mø) or neutrophils (PMN) were stimulated with 200
ng/mL CXCL12 and cell free supernatants were collected after 24
hours and added to either HeLa or DLD-1 cells. (B) Supernatants
from CXCL12-stimulated PMN (SN1) were not effective at inducing
phosphorylation of HER1, because PMN did not produce HB-EGF.
Supernatants from CXCL12-stimulated Mø (SN2) induced HER1
phosphorylation at Y1068 when added to HeLa or DLD-1 cells (p <
0.05). The phosphorylation was genuinely inhibited by 100 μg/mL
anti-HB-EGF neutralising Abs. (C) SN2 caused HeLa and DLD-1 cells
to proliferate to a degree that was comparable to stimulation with
25 ng/mL HB-EGF. The means ± SD of 10 experiments are depicted.
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Page 7 of 13Moreover, the metastatic colon cancer cells stained posi-
tive for HER4 (Figure 1), through which HB-EGF exerts
powerful chemotactic activity [19]. Thus, HB-EGF can
induce cancer cell chemotaxis and proliferation as well
as microenvironment-targeted angiogenic signals.
Finally, Figure 6B shows that HB-EGF conferred upon
HeLa and DLD-1 cells both proliferative and anti-
apoptotic signals; these latter signals clearly emerged
under starvation conditions, as indicated by the statisti-
cally significant reduction in mono/oligonucleosomes
released into the cytoplasm.
CXCL12 and HB-EGF induce cancer cells to synthetise and
release GM-CSF
In addition, when HeLa and DLD-1 cancer cells were
stimulated with 200 ng/mL CXCL12 and/or 25 ng/mL
HB-EGF, GM-CSF proteins were detected by immuno-
cytochemistry after 24 hours and new GM-CSF tran-
scripts (as assessed by RT-PCR) appeared after 2 hours
(Figure 7A, B). Conditioned medium obtained from can-
cer cells contained GM-CSF (Figure 8A) and induced
HB-EGF expression in, and release from, mononuclear
phagocytes (Figures 7C; 8B). Inhibitory anti-GM-CSF
mAbs significantly reduced the production of HB-EGF
(Figure 8B). Thus, CXCL12 and HB-EGF induced GM-
CSF expression in HeLa and DLD-1 cancer cells.
Paracrine loop activated by CXCL12
As described above, CXCL12 was shown to prompt
mononuclear phagocytes and cancer cells to release
HB-EGF and GM-CSF, respectively. On the other hand,
we have previous evidence showing that GM-CSF is a
strong inducer of HB-EGF expression in mononuclear
phagocytes [19,20]. If HB-EGF released by mononuclear
phagocytes can trigger the production of GM-CSF in
cancer cells, a possible GM-CSF/HB-EGF paracrine
loop may exist that is initially activated by CXCL12.
Thus, we tested (i) HeLa and DLD-1 cancer cells for
the production of GM-CSF upon HB-EGF stimulation
and (ii) mononuclear phagocytes for the production of
HB-EGF upon GM-CSF stimulation. This choice was
based on the known differential receptor expression in
mononuclear phagocytes, as opposed to cancer cells,
which are usually negative for the GM-CSF receptor.
Figure 7 depicts the experiments suggesting that a
paracrine loop exists between Mø and HeLa or DLD-1
cancer cells. When these cancer cells were stimulated
with 200 ng/mL CXCL12 and/or 25 ng/mL HB-EGF,
they produced and released GM-CSF (Figures 7A, B;
8A). When mononuclear phagocytes were stimulated
with CXCL12 and/or 25 ng/mL GM-CSF, they pro-
duced and released HB-EGF (Figures 2; 7B, C, D; 8B).
HB-EGF mRNA transcripts and membrane protein
levels were increased after 2 hours (Figures 2B; 7B) and
after 24 hours of stimulation (Figures 2A, C; 7C, D; 8B).
These results were reproduced by the addition of condi-
tioned medium from mononuclear phagocytes to cancer
cells and vice versa (Figures 7A, C; 8). Inhibitory anti-HB-
EGF and anti-GM-CSF Abs significantly reduced the
production of GM-CSF by cancer cells (Figure 8A) and
HB-EGF by mononuclear phagocytes (Figure 8B), respec-
tively. Thus, a paracrine loop may exist between mono-
nuclear phagocytes and HeLa or DLD-1 cancer cells, as
exemplified in Figure 7E. CXCL12 seems to act as an addi-
tive or synergistic agent in this positive feedback loop. The
expression of these molecules as found in patient biopsy
samples (Figure 1) is in line with and corroborates our
findings in vitro.
Figure 6 Angiogenic, proliferative and anti-apoptotic activities of HB-EGF. (A) HB-EGF or supernatants from CXCL12-stimulated
mononuclear phagocytes (SN2) induced stromal (Balb/c 3T3) and endothelial (HUVEC) cells to proliferate, which shows that both HB-EGF and
the evaluated supernatants share angiogenic potential. The supernatant-associated angiogenic signals were inhibited by 100 μg/mL anti-HB-EGF
neutralising Abs (p < 0.05). (B) HB-EGF induced proliferation and anti-apoptotic effects (p < 0.05) in HeLa (blue) and DLD-1 (red) cells. Cultures
were performed in serum free medium in the absence (△) or presence (□) of 25 ng/mL HB-EGF. Proliferation was evaluated by an MTT assay
after 24, 48 and 72 hours in culture. Apoptosis was evaluated at 72 hours by the detection of internucleosomal DNA fragmentation by a specific
ELISA. The ratio between absorbance of untreated and treated cells (enrichment factor, EF) was used as an index of rescue from apoptosis due
to serum deprivation. The means ± SD of 5 experiments are depicted.
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To further test the GM-CSF/HB-EGF loop between can-
cer cells and macrophages, we established a siRNA
sequence targeted against GM-CSF. This siRNA effi-
ciently blocked GM-CSF induction and release in HeLa
and DLD-1 cells in response to both HB-EGF
(Figure 9A) and conditioned medium from mononuclear
phagocytes (data not shown). Similarly, inhibitory anti-
HB-EGF Abs significantly reduced the production of
GM-CSF by cancer cells (Figure 8A). Therefore, HB-
EGF genuinely and specifically induced GM-CSF expres-
sion in these cells. The supernatant from silenced cancer
cells lost the ability to upregulate HB-EGF in mononuc-
lear phagocytes (Figure 9B) and inhibitory anti-GM-CSF
Abs blocked the induction of HB-EGF (Figure 8B),
showing that the upregulation was specifically due to
Figure 7 GM-CSF/HB-EGF paracrine loop between mononuclear phagocytes and cancer cells. (A) HeLa and DLD-1 cells produced GM-CSF
following stimulation with 200 ng/mL CXCL12 and/or 25 ng/mL HB-EGF or supernatants obtained by treating human mononuclear phagocytes
(Mø SN) with 25 ng/mL GM-CSF for 24 hours. (B) RT-PCR for GM-CSF in HeLa cells and Northern blot for HB-EGF in Mø stimulated as noted in
the captions. (C) Mø upregulated HB-EGF surface expression following stimulation with GM-CSF, CXCL12 or cancer supernatants (cancer SN) that
were obtained by GM-CSF-positive HeLa/DLD-1 cells. (D) Mø released HB-EGF (p < 0.05) upon GM-CSF or CXCL12 stimulation, as measured by a
specific ELISA. Representative pictures or the means ± SD out of 10 experiments are shown. (E) Mechanistic representation of paracrine loops as
suggested by the experimental findings.
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Page 9 of 13GM-CSF. Finally, mononuclear phagocytes treated with
supernatants from GM-CSF-silenced cancer cells lost
the ability to induce GM-CSF in non-silenced cancer
cells (Figure 9C). Thus, GM-CSF silencing data comple-
ment the ligand-blocking experiments obtained with
inhibitory Abs, and strengthen our experimental
evidence supporting the existence of an activated GM-
CSF/HB-EGF loop between cancer cells and mononuc-
lear phagocytes. When available, HB-EGF specifically
stimulates cancer cells to produce GM-CSF, and the
reciprocal availability of the two factors activates a posi-
tive feedback loop between them (Figure 7E).
Discussion
The current study defines a novel mechanism whereby
CXCL12 redirects macrophages to promote a microen-
vironment that is suitable for cancer survival via aG M -
CSF/HB-EGF paracrine loop. To our knowledge, there
are no other studies showing that human mononuclear
phagocytes release and up-regulate HB-EGF, while
cancer cells release and upregulate GM-CSF, when
stimulated with CXCL12.
By evaluating histological samples from human colon
cancer metastases in the liver, we observed that numer-
ous HB-EGF/CXCR4-positive macrophages, which
expressed both the M1 CXCL10 and the M2 CD163
markers, indicating a mixed M1/M2 microenvironment,
infiltrated metastatic cancer cells. These in turn were
positive for CXCR4, CXCL12, GM-CSF and HER1
(Figure 1). We then validated the mutual interactions asso-
ciated with this repertoire of molecules in standard and
transwell experiments performed on human mononuclear
phagocytes and HeLa and DLD-1 cancer cell lines, expres-
sing the same molecules in the same cellular distribution
as macrophages and cancer in biopsy samples.
CXCL12 and GM-CSF induced mononuclear phago-
cytes to synthetise and release HB-EGF. Northern blotting
of RNA from kinetic experiments revealed that maximal
expression of HB-EGF mRNA occurred between 2 and 24
hours after CXCL12- or GM-CSF-dependent induction,
leading to an increase in membrane HB-EGF molecule
density (Figures 2; 7B, C). In transwell experiments,
CXCL12-stimulated mononuclear phagocytes released
HB-EGF that caused the phosphorylation of HER1 in
HeLa and DLD-1 target cells (Figure 4B). Cell-free super-
natants from CXCL12-treated mononuclear phagocytes
induced HER1 phosphorylation followed by cellular prolif-
eration in either HeLa or DLD-1 cells, an effect that was
inhibited by anti-HB-EGF neutralising Abs (Figure 5).
Stimulation with CXCL12, HB-EGF or both induced
GM-CSF transcripts in HeLa and DLD-1 cells. At 24
hours, immunocytochemistry revealed clear-cut staining
for GM-CSF in both cell lines (Figure 7A). Their condi-
tioned medium contained GM-CSF that induced Mø to
produce HB-EGF (Figures 7C; 8B). Conversely, mono-
nuclear phagocytes conditioned medium contained HB-
EGF that induced cancer cells to produce GM-CSF
(Figures 7A; 8A). These effects were largely counter-
acted by the addition of specific neutralising Abs (Figure
8) or by GM-CSF silencing (Figure 9). In conclusion,
CXCL12 induced HB-EGF in mononuclear phagocytes
and GM-CSF in HeLa and DLD-1 cancer cells, activat-
ing or enhancing a GM-CSF/HB-EGF paracrine loop.
Thus, we have evidence for a specific pathway of acti-
vation in mononuclear phagocytes (CXCL12-stimulated
Mø release of HB-EGF) that may match the specific
Figure 8 GM-CSF and HB-EGF release from cancer cells and
mononuclear phagocytes. ELISA analysis (see Methods section)
revealed that GM-CSF and HB-EGF were barely detectable under
basal conditions in supernatants from HeLa/DLD-1 cells or
mononuclear phagocytes, respectively, but accumulated 24 hours
after stimulation. (A) Stimulation of HeLa/DLD-1 with 25 ng/mL HB-
EGF or supernatant from mononuclear phagocytes (SN2) induced
GM-CSF release into supernatants. 100 μg/mL anti-HB-EGF blocking
Abs reduced the supernatant-dependent release (p < 0.05). (B)
Stimulation of mononuclear phagocytes with 25 ng/mL GM-CSF or
supernatant from GM-CSF-positive cancer cells (SN) led to the
accumulation of HB-EGF in supernatants. 100 μg/mL anti-GM-CSF
neutralising Abs suppressed the supernatant-dependent release (p <
0.05). The means ± SD out of 10 experiments are depicted.
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Page 10 of 13biological properties of some cancers (HeLa, DLD-1 and
metastatic colon cancer). We have also documented a
specific pathway of activation in cancer cells (CXCL12/
HB-EGF-stimulated cancer cell release of GM-CSF) that
may match the specific biological properties of mono-
nuclear phagocytes. This interplay between mononuclear
phagocytes and cancer cells may lead to an inflamma-
tory environment that favours rather than inhibits
tumour growth. Furthermore, both macrophages and
cancer cells were activated upon CXCL12 stimulation in
liver biopsies (Figure 1), though we could not conclu-
sively establish whether cancer cells produced their own
CXCL12 or merely internalized CXCL12, produced by
stromal cells. Other studies have demonstrated that
CXCL12 transactivates HER2 in breast cancer cells [25],
enhancing the expression of CXCR4 and favouring
metastases [11]. In our work, CXCL12 has been shown
to transactivate HER1 and induce GM-CSF. The latter is
a specific inducer of HB-EGF, which in turn binds to
HER1. HB-EGF acts as a chemotactic, pro-growth and
anti-apoptotic factor in cancer cells, and plays a role as
angiogenic factor by inducing endothelial cells and
fibroblasts to proliferate (Figure 6). It also promotes
angiogenesis by induction of VEGF [20]. In general, HB-
EGF is a powerful inducer of fibroblast activities
[17,19,20] that are involved in orchestrating inflamma-
tion and promoting tumour growth, angiogenesis and
recruitment of macrophages and cancer cells [7].
Therefore, the CXCL12 receptors, CXCR4 and
CXCR7, should be thought of as a node that connects
multiple loops [26-30], including the highly important
EGF/HER loops [13], linking cancer (oncogenes) and
inflammation [5]. Based on our previous demonstration
of the role of HER1 in the regulation of mesenchymal
stem cell proliferation and differentiation [16], as well as
on some general models [5,31,32], we speculate that the
crosstalk between CXCL12/CXCR4 and HB-EGF/HERs
may contribute to the balance between the HER1-
dependent cellular responses of differentiation and self-
renewal [31-34].
Figure 9 Knockdown of GM-CSF protein levels after siRNA application in cancer cells. HeLa/DLD-1 cells were transfected with control
siRNA (1/1*, 2/2*) or GM-CSF siRNA (3/3*, 4/4*) and cultured in the absence or presence of 25 ng/mL HB-EGF. The numbers indicate the culture
conditions and the corresponding supernatants (SN) used for ELISA or cell stimulation. (A) Blockade of GM-CSF production in cultures of HeLa/
DLD-1 cells transfected with GM-CSF siRNA was confirmed by immunocytochemistry (2/2* vs. 4/4*) and ELISA (left side; 2/2* vs. 4/4*, p < 0.05).
(B) SN from GM-CSF-silenced HeLa/DLD-1 did not induce HB-EGF expression in mononuclear phagocytes (Mø), as revealed by flow cytometry (2/
2* vs. 4/4*) and ELISA (left side; 2/2* vs. 4/4*, p < 0.05). (C) Mø stimulated with SN from GM-CSF-silenced HeLa/DLD-1 cells released SN less
effective at inducing GM-CSF in non-silenced cancer cells, as determined by ELISA (see Methods section; SN2 vs. SN4, p < 0.05). Representative
pictures or the means ± SD out of 5 experiments are shown.
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This study provides evidence that CXCL12 partecipates
in the selective production of cytokines, leading to a
GM-CSF/HB-EGF paracrine loop that may favour neo-
plastic growth. CXCL12 has chemotactic activity
towards cancer and immune cells; in both cell types, it
induces cytokines that retainp r o - t u m o u ra c t i v i t ya n d
modulate the stromal component [7,16], contributing to
a tumour-permissive microenvironment. Therefore,
CXCL12 signalling may provide a unifying basis for bet-
ter understanding the complex relationships between
cancer and inflammatory cells in terms of receptor
crosstalk. For instance, the involvement of mixed M1/
M2, GM-CSF-stimulated macrophages in a tumour-
promoting loop challenges the view of tumour-permis-
sive macrophages as polarized M2 mononuclear phago-
cytes and hints at contexts in which pro-inflammatory
microenvironments may allow effective tumour-promot-
ing activities through mediators such as GM-CSF and
HB-EGF. These mediators, indeed, seem to play a role
that favours both cancer and a shift towards a M1-
polarized microenvironment. Eventually, such an under-
standing could contribute to the development of tools
to interfere with recognised pathogenic signals [35].
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